SS-31 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways. Proper stacking requires understanding each compound's mechanism and timing.
What Is SS-31 Stacking?
Stacking means combining SS-31 with one or more complementary peptides to potentially achieve synergistic effects. Because different peptides work through different mechanisms, strategic combinations can target multiple pathways simultaneously.
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What Is the Best SS-31 Stack?
Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways.
This combination is popular because it targets multiple mechanisms without significant overlap in side-effect profiles.
How Does SS-31 Stack With MOTS-C?
MOTS-C (Mitochondrial ORF of the 12S rRNA Type-C) is a Mitochondrial-derived peptide, metabolic regulator that works through Translocates to the nucleus where it regulates gene expression through the Folate-AICAR-AMPK pathway. Activates antioxidant response elements (ARE) an.
Combined with SS-31's effects on improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction, this stack covers improved insulin sensitivity, glucose metabolism, fat loss, lean muscle preservation, exercise capacity enhancement, anti-aging, metabolic flexibility as well.
Typical stacking protocol: SS-31 at 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV daily subcutaneous or weekly IV infusion alongside MOTS-C at 5-10 mg per week 2-3 times weekly. See our MOTS-C guide for details.
How Do You Time a SS-31 Stack?
When stacking, timing each injection based on half-life is important. SS-31 has a half-life of approximately 20-30 minutes, which influences when to administer relative to other compounds.
Some researchers inject all peptides at the same time; others stagger by 15-30 minutes. There's limited data on whether timing within the same session matters significantly.
What Should You NOT Stack With SS-31?
Avoid stacking peptides with similar mechanisms of action at full doses — this can lead to receptor desensitization without proportional benefit. Also avoid combining compounds where side-effect profiles overlap significantly.
When in doubt, introduce one new compound at a time to isolate its effects before building a full stack.
Calculate Your SS-31 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for SS-31.
Open Calculator →Bottom Line on SS-31 Stacking
Pairs with MOTS-C for comprehensive mitochondrial optimization — SS-31 stabilizes existing mitochondria while MOTS-C activates new mitochondrial biogenesis pathways. Start with a single compound, assess response, then add complements.
See our stacking and cycling guide for general principles.
Complete Guide
SS-31 (Elamipretide) : Mitochondrial Peptide for Energy & Aging
Related Reading
- SS-31 Dosage Guide
- SS-31 Benefits
- SS-31 Side Effects
- SS-31 Cycle Guide
- SS-31 Research
- MOTS-C Complete Guide
Research-Grade Sourcing
If you're going to research SS-31, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is SS-31?
SS-31 (Elamipretide (SS-31)) is a Mitochondrial-targeting tetrapeptide. Synthetic tetrapeptide co-discovered for mitochondrial dysfunction disorders; developed by Stealth BioTherapeutics. It is researched for improved muscle strength, enhanced cardiac function, increased ATP production, reduced oxidative stress, restored age-related mitochondrial dysfunction.
What is the recommended SS-31 dosage?
Common dosages: 4-40 mg daily (subcutaneous); 0.01-0.25 mg/kg/hour IV administered daily subcutaneous or weekly IV infusion via subcutaneous injection or intravenous infusion. Cycle length: 12-48 weeks in clinical trials. Half-life: approximately 20-30 minutes. Use our peptide calculator for exact reconstitution math.
What are the side effects of SS-31?
Excellent safety profile. No adverse events reported in single-dose IV studies. Well-tolerated across wide dose ranges in long-term Phase 2 and 3 trials.
Is SS-31 safe?
SS-31 has shown a favorable safety profile in research. FDA-approved September 2025 (FORZINITY) for Barth syndrome. Phase 3 trials ongoing for other indications. All research should follow appropriate safety protocols.